Form 4: Janux Therapeutics Chief Medical Officer Receives Stock Options and Restricted Stock Units

Janux Therapeutics' Chief Medical Officer, Zachariah McIver, was granted 91,000 stock options and 26,000 restricted stock units on January 2, 2025.

Summary

• Zachariah McIver, the Chief Medical Officer of Janux Therapeutics, received 26,000 restricted stock units (RSUs) and 91,000 stock options on January 2, 2025.
• The RSUs vest in four equal annual installments starting January 1, 2026.
• The stock options vest 25% on January 1, 2026, with the remaining balance vesting monthly over the following three years.
• The exercise price for the stock options is $53.24 per share.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options and RSUs aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

This type of equity grant is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Equity grants are a standard component of compensation packages for executives in the biotech industry.
• Vesting schedules, such as the four-year vesting for RSUs and a combination of cliff and monthly vesting for options, are typical in the industry.
• The specific amounts of equity granted would be compared to similar roles at comparable companies to determine if they are in line with industry standards.

Stakeholder Impact

• Shareholders may view this as a positive sign of incentivizing key management.
• Employees may see this as a standard practice for executive compensation.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, Janux Therapeutics, vesting, Chief Medical Officer, equity